Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Nykode Therapeutics A stock

NYKD.OL
NO0010714785
A2PZ5J

Price

0.20
Today +/-
+0.01
Today %
+6.87 %

Nykode Therapeutics A stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Nykode Therapeutics A stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Nykode Therapeutics A stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Nykode Therapeutics A stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Nykode Therapeutics A's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Nykode Therapeutics A Stock Price History

DateNykode Therapeutics A Price
3/5/20250.20 undefined
3/4/20250.18 undefined
3/3/20250.21 undefined
2/28/20250.23 undefined
2/27/20250.22 undefined
2/26/20250.23 undefined
2/25/20250.23 undefined
2/24/20250.23 undefined
2/21/20250.23 undefined
2/20/20250.23 undefined
2/19/20250.22 undefined
2/18/20250.22 undefined
2/17/20250.21 undefined
2/14/20250.22 undefined
2/13/20250.20 undefined
2/12/20250.21 undefined
2/11/20250.21 undefined
2/10/20250.22 undefined
2/7/20250.22 undefined
2/6/20250.23 undefined

Nykode Therapeutics A Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nykode Therapeutics A, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nykode Therapeutics A from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nykode Therapeutics A’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nykode Therapeutics A. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nykode Therapeutics A’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nykode Therapeutics A’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nykode Therapeutics A’s growth potential.

Nykode Therapeutics A Revenue, EBIT and net profit per share

DateNykode Therapeutics A RevenueNykode Therapeutics A EBITNykode Therapeutics A Net Income
2029e737.58 M undefined-698.46 M undefined-526.23 M undefined
2028e113.76 M undefined-434.45 M undefined-424.74 M undefined
2027e6.8 M undefined-497.07 M undefined-486 M undefined
2026e1.22 M undefined-37.84 M undefined-42.19 M undefined
2025e3.91 M undefined-34.01 M undefined-36.64 M undefined
2024e3.76 M undefined-56.61 M undefined-45.97 M undefined
202312.9 M undefined-56.36 M undefined-35.15 M undefined
20227.17 M undefined-50.66 M undefined-42.74 M undefined
202133.96 M undefined-7.73 M undefined-9.41 M undefined
2020215 M undefined181.34 M undefined149.77 M undefined
20190 undefined-13.19 M undefined-13.7 M undefined
201812,700 undefined-6.51 M undefined-6.31 M undefined
201748,100 undefined-3.36 M undefined-3.1 M undefined
201624,000 undefined-1.62 M undefined-1.6 M undefined

Nykode Therapeutics A Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000215337123316113737
------84.65-78.7971.43-75.00--66.67500.001,783.33552.21
----100.00106.06128.5775.00300.00300.00900.00150.007.961.22
00012153590000000
-1-3-6-13149-9-42-35-45-36-42-485-424-526
-200.00100.00116.67-1,246.15-106.04366.67-16.6728.57-20.0016.671,054.76-12.5824.06
55.855.855.854.97296.15286.34290.12300.52000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Nykode Therapeutics A Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nykode Therapeutics A is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
2.4720.4114.231.59208.32227.93205.84161.95
000018.7523.752.540
00.6901.261.342.411.791.07
00000000
00.070.090.320.631.781.72.66
2.4721.1714.333.17229.03255.86211.87165.68
0.010.010.010.170.419.179.5310.52
00000000
000.0100.550.48031.92
29.729.629.63432323270
00000000
0005523468
0.040.040.050.2119.79.642.51
2.5121.2114.3533.39230.03265.56221.48208.19
               
20.830.240.240.320.330.330.340.37
7.7928.4328.4759.1360.3581.5383.32128.99
-5.44-8.54-14.85-31.08121.29115.3276.4144.95
000-0.73-3.11-3.12-3.05-3.05
00000000
23.1920.1313.8627.63178.85194.06157.02171.26
0.340.60.551.521.612.752.311.33
0000.645.964.065.14.21
1.40.480.772.15.3423.2130.4313.62
00000000
0000.060.281.351.151.46
1.741.081.314.3213.1831.3738.9920.61
0000.030.015.824.374.27
000031.1329.421.0812.05
0001.46.864.910.030
0001.443840.1325.4716.32
1.741.081.315.7551.1871.564.4636.93
24.9321.2115.1733.39230.03265.56221.48208.19
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Nykode Therapeutics A provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nykode Therapeutics A's financial health and stability.

Assets

Nykode Therapeutics A's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nykode Therapeutics A must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nykode Therapeutics A after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nykode Therapeutics A's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-1-3-6-13180-11-50-44
00000012
00000000
0000-10-724-29
00029193-25
00000000
00000000
-1-2-6-101801-20-96
000000-2-1
000-9-610117
000-8-511138
00000000
000000-10
220026021145
220025020044
--------
00000000
018-6617332-9-43
-1.61-2.87-6.36-10.57180.170.28-23.37-98.53
00000000

Nykode Therapeutics A stock margins

The Nykode Therapeutics A margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nykode Therapeutics A. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nykode Therapeutics A.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nykode Therapeutics A's sales revenue. A higher gross margin percentage indicates that the Nykode Therapeutics A retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nykode Therapeutics A's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nykode Therapeutics A's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nykode Therapeutics A's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nykode Therapeutics A. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nykode Therapeutics A's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nykode Therapeutics A Margin History

Nykode Therapeutics A Gross marginNykode Therapeutics A Profit marginNykode Therapeutics A EBIT marginNykode Therapeutics A Profit margin
2029e125.98 %-94.7 %-71.35 %
2028e125.98 %-381.9 %-373.37 %
2027e125.98 %-7,309.93 %-7,147.04 %
2026e125.98 %-3,091.67 %-3,447.01 %
2025e125.98 %-870.85 %-938.26 %
2024e125.98 %-1,506.79 %-1,223.45 %
2023125.98 %-436.82 %-272.47 %
2022125.98 %-706.81 %-596.3 %
2021105.32 %-22.75 %-27.72 %
2020100.33 %84.34 %69.66 %
2019125.98 %0 %0 %
2018125.98 %-51,278.74 %-49,686.62 %
2017125.98 %-6,985.45 %-6,451.35 %
2016125.98 %-6,762.5 %-6,685 %

Nykode Therapeutics A Stock Sales Revenue, EBIT, Earnings per Share

The Nykode Therapeutics A earnings per share therefore indicates how much revenue Nykode Therapeutics A has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nykode Therapeutics A earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nykode Therapeutics A's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nykode Therapeutics A’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nykode Therapeutics A's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nykode Therapeutics A Revenue, EBIT and net profit per share

DateNykode Therapeutics A Sales per ShareNykode Therapeutics A EBIT per shareNykode Therapeutics A Earnings per Share
2029e2.26 undefined0 undefined-1.61 undefined
2028e0.35 undefined0 undefined-1.3 undefined
2027e0.02 undefined0 undefined-1.49 undefined
2026e0 undefined0 undefined-0.13 undefined
2025e0.01 undefined0 undefined-0.11 undefined
2024e0.01 undefined0 undefined-0.14 undefined
20230.04 undefined-0.19 undefined-0.12 undefined
20220.02 undefined-0.17 undefined-0.15 undefined
20210.12 undefined-0.03 undefined-0.03 undefined
20200.73 undefined0.61 undefined0.51 undefined
20190 undefined-0.24 undefined-0.25 undefined
20180 undefined-0.12 undefined-0.11 undefined
20170 undefined-0.06 undefined-0.06 undefined
20160 undefined-0.03 undefined-0.03 undefined

Nykode Therapeutics A business model

Vaccibody AS is a Norwegian biotechnology company that was founded in 2007. It is headquartered in Oslo and currently employs about 40 people. The company specializes in the development of individualized vaccines based on DNA-based technology. The idea for founding Vaccibody came about when the two founders, Agnete Fredriksen and Bjarne Bogen, were collaborating at the University of Oslo. They wanted to develop a method to personalize vaccines in order to increase their effectiveness and compatibility. Their discovery is based on the fact that T-cells play an important role in the immune system and can recognize specific target proteins produced by cancer cells or viruses. Vaccibody's business model is based on the development of individualized vaccines based on DNA-based technology. The company has several different areas, including cancer immunotherapy, infectious diseases, and personalized medicine. Vaccibody's vaccines can be used for various types of cancer, such as lung, breast, and prostate cancer. Vaccibody offers a range of products, including a vaccine against HPV (human papillomavirus) that is approved for women aged 9 to 45. This vaccine aims to reduce the risk of cervical cancer. Another product from Vaccibody is the prostate cancer vaccine VCD-001. This vaccine uses the antigen PSA (prostate-specific antigen), which occurs on the surface of prostate cancer cells, to stimulate the patient's immune system. Vaccibody is also working on the development of vaccines against COVID-19 and has already achieved initial positive results in preclinical studies. As part of its personalized medicine division, Vaccibody offers the DNA platform VACCIBODY®, which is used to manufacture individualized DNA vaccines. This technology allows the vaccine to be tailored specifically to the needs of each patient. Vaccibody has achieved many important milestones since its inception. In 2018, the company received a $12.5 million investment to further develop its cancer immunotherapy platform. In 2020, Vaccibody received an additional $43.5 million investment to advance the development of its COVID-19 vaccine. Overall, Vaccibody has the potential to change the way vaccines are developed and used. DNA-based technology offers many advantages over conventional vaccines, especially in personalized medicine. Vaccibody is working hard to further develop its technology and bring its products to market in order to improve the lives of people around the world. Nykode Therapeutics A is one of the most popular companies on Eulerpool.com.

Nykode Therapeutics A SWOT Analysis

Strengths

1. Advanced technology and expertise in the development of therapeutic vaccines.

2. Strong intellectual property portfolio providing a competitive advantage in the market.

3. Strategic collaborations with reputable pharmaceutical companies, enhancing research and development capabilities.

4. Well-established network of research partners and key opinion leaders in the field.

Weaknesses

1. Relatively small size and limited resources compared to larger pharmaceutical companies.

2. Dependency on successful clinical trial outcomes to generate revenues.

3. Limited product portfolio with focus on specific therapeutic areas.

Opportunities

1. Increasing demand for personalized medicine and targeted therapies.

2. Growing global healthcare expenditure, providing opportunities for market expansion.

3. Emerging markets with unmet medical needs, offering potential for partnerships and market penetration.

Threats

1. Intense competition from established pharmaceutical companies and new entrants in the field of therapeutic vaccines.

2. Stringent regulatory requirements and approval processes for drug development.

3. Potential risks associated with adverse events during clinical trials, leading to setbacks and negative publicity.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Nykode Therapeutics A Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Nykode Therapeutics A historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Nykode Therapeutics A shares outstanding

The number of shares was Nykode Therapeutics A in 2024 — This indicates how many shares 300.52 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nykode Therapeutics A earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nykode Therapeutics A's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nykode Therapeutics A’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nykode Therapeutics A's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Nykode Therapeutics A.

Nykode Therapeutics A latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.04 -0.03  (32.13 %)2024 Q3
6/30/2024-0.06 -0.02  (68.7 %)2024 Q2
3/31/2024-0.05 -0.05  (2.04 %)2024 Q1
12/31/2023-0.54 -0.22  (60.17 %)2023 Q4
9/30/2023-0.58 -0.31  (45.76 %)2023 Q3
6/30/2023-0.53 -0.32  (39.23 %)2023 Q2
3/31/2023-0.53 -0.41  (22.57 %)2023 Q1
12/31/2022-0.41 -0.41  (0.03 %)2022 Q4
1

Nykode Therapeutics A shareholders

%
Name
Stocks
Change
Date
9.24231 % Rasmussengruppen AS30,180,75006/30/2024
7.96203 % Datum Opportunity AS26,000,00006/30/2024
5.42189 % AS Tanja17,705,17506/30/2024
4.60879 % Capital Research Global Investors15,050,000012/31/2024
3.98002 % Norda ASA12,996,7555,000,00011/8/2024
3.84635 % Datum AS12,560,25006/30/2024
3.23431 % Joh Johannson Eiendom AS10,561,63106/30/2024
3.15888 % Radforsk Investeringsstiftelse10,315,311-13,741,6899/27/2024
2.00164 % Vatne Equity AS6,536,344-949,5133/31/2024
1.99649 % OM Holding AS6,519,52506/30/2024
1
2
3
4
5
...
9

Nykode Therapeutics A Executives and Management Board

Mr. Michael Engsig

Nykode Therapeutics A Chief Executive Officer
Compensation 567,000

Mr. Anders Tuv

Nykode Therapeutics A Director (since 2017)
Compensation 82,000

Dr. Bernd Seizinger

(66)
Nykode Therapeutics A Director
Compensation 53,000

Mr. Christian Abyholm

Nykode Therapeutics A Director
Compensation 33,000

Dr. Birgitte Volck

(60)
Nykode Therapeutics A Director
Compensation 29,000
1
2
3
4

Most common questions regarding Nykode Therapeutics A

What values and corporate philosophy does Nykode Therapeutics A represent?

Vaccibody AS represents a set of core values and corporate philosophy that drives its operations. The company places a strong emphasis on innovation, striving to develop cutting-edge solutions in the field of immunotherapy. With a focus on precision medicine, Vaccibody AS aims to enhance patient outcomes by tailoring treatments to individual needs. The company is committed to scientific excellence, fostering collaborations to advance research and development efforts. Vaccibody AS also upholds principles of transparency and ethical conduct, ensuring the highest standards of integrity throughout its operations. Overall, the company's values and corporate philosophy revolve around pushing the boundaries of medical innovation to address unmet needs in healthcare while prioritizing patient-centricity.

In which countries and regions is Nykode Therapeutics A primarily present?

Vaccibody AS is primarily present in Norway, with its headquarters located in Oslo. As a biotechnology company, Vaccibody AS focuses on developing innovative immunotherapies and targeted treatments for various diseases. While primarily based in Norway, Vaccibody AS also collaborates with academic institutions, research organizations, and pharmaceutical companies worldwide to advance its technologies and reach a broader global audience. With its dedication to revolutionize healthcare solutions, Vaccibody AS is committed to making a positive impact on the lives of patients not only in Norway but also around the globe.

What significant milestones has the company Nykode Therapeutics A achieved?

Vaccibody AS, a leading biotechnology company, has achieved several significant milestones. The company successfully completed a Phase I clinical trial for its individualized therapeutic cancer vaccine, VB10.NEO. This trial demonstrated the vaccine's safety and ability to induce immune responses against cancer-specific mutations. Vaccibody AS also entered into a strategic collaboration with Genentech, a member of the Roche Group, to develop personalized cancer vaccines using Vaccibody's proprietary platform. Additionally, the company secured a research grant from the European Union's Horizon 2020 program to further advance its innovative pipeline. These accomplishments highlight Vaccibody AS's dedication towards revolutionizing cancer treatment through the development of highly targeted and personalized therapies.

What is the history and background of the company Nykode Therapeutics A?

Vaccibody AS is a Norwegian biotechnology company specializing in the development of therapeutic vaccines to treat cancer. Founded in 2006, the company has a rich history in the field of innovative immunotherapies. Vaccibody AS aims to harness the body's immune system to fight cancer cells effectively. With a focus on precision medicine, the company has developed a versatile and scalable platform technology known as the Vaccibody Vaccine technology. This technology has shown promising results in preclinical and clinical trials, demonstrating its potential in improving patient outcomes. Vaccibody AS continues to advance its research and development efforts to address unmet medical needs and make meaningful contributions to the field of cancer therapeutics.

Who are the main competitors of Nykode Therapeutics A in the market?

The main competitors of Vaccibody AS in the market include companies such as Genocea Biosciences, Moderna Therapeutics, BioNTech SE, and Inovio Pharmaceuticals.

In which industries is Nykode Therapeutics A primarily active?

Vaccibody AS is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Nykode Therapeutics A?

The business model of Vaccibody AS is focused on the development and commercialization of immunotherapies for the treatment of cancer and infectious diseases. Vaccibody utilizes a unique platform technology known as the Vaccibody Virus-Like Particle (VLP) platform, which enables the design and production of specifically targeted vaccines. By leveraging this platform, Vaccibody aims to create personalized and precise therapeutics that activate the body's immune system to fight against these diseases. Through continuous research and collaboration, Vaccibody AS aims to revolutionize the field of immunotherapy and provide effective treatments for patients.

What is the P/E ratio of Nykode Therapeutics A 2025?

The Nykode Therapeutics A P/E ratio is -1.62.

What is the P/S ratio of Nykode Therapeutics A 2025?

The Nykode Therapeutics A P/S ratio is 15.2.

What is the Quality Investing of Nykode Therapeutics A?

The Quality Investing for Nykode Therapeutics A is 1/10.

What is the revenue of Nykode Therapeutics A 2025?

The expected Nykode Therapeutics A revenue is 3.91 M USD.

How high is the profit of Nykode Therapeutics A 2025?

The expected Nykode Therapeutics A profit is -36.64 M USD.

What is the business model of Nykode Therapeutics A

Vaccibody AS is a Norwegian biotechnology company specializing in the development of personalized cancer vaccines. The company's business model is based on utilizing its proprietary technology platform, which is based on DNA molecules called plasmids. The company offers a wide range of products and services, including: 1. Vaccibody platform: Vaccibody's DNA platform has been developed to create tailor-made vaccines for fighting cancer and infectious diseases. The platform utilizes the body's own immune response to combat tumor cells and harmful pathogens and reduce disease symptoms. 2. Vaccines: Vaccibody's vaccines can be customized for each individual patient to trigger an optimal immune response against the tumor or disease-causing virus. The vaccine is made from the patient's genetic material, allowing for personalized therapy. 3. Drug delivery: Vaccibody has also developed a unique targeted drug delivery method. The platform utilizes the ability of antibodies to recognize specific cells in the body to enable targeted drug delivery. This approach reduces the dosage required for effective therapy and therefore minimizes side effects. 4. Partnerships: Vaccibody collaborates with leading pharmaceutical and biotech companies to accelerate the development and commercialization of their technology platform. This collaboration includes the development of vaccines and drugs based on the Vaccibody platform, as well as licensing and selling patents and technologies. Overall, Vaccibody's business model aims to develop personalized therapy for cancer and infectious diseases based on the body's own immune response. By utilizing its proprietary technology platform and collaborating with partners in the pharmaceutical industry, the development and commercialization of vaccines and drugs are expedited. The output is: Vaccibody AS is a Norwegian biotechnology company specializing in the development of personalized cancer vaccines. The company's business model is based on utilizing its proprietary technology platform, which is based on DNA molecules called plasmids.

What is the Nykode Therapeutics A dividend?

Nykode Therapeutics A pays a dividend of 0 USD distributed over payouts per year.

How often does Nykode Therapeutics A pay dividends?

The dividend cannot currently be calculated for Nykode Therapeutics A or the company does not pay out a dividend.

What is the Nykode Therapeutics A ISIN?

The ISIN of Nykode Therapeutics A is NO0010714785.

What is the Nykode Therapeutics A WKN?

The WKN of Nykode Therapeutics A is A2PZ5J.

What is the Nykode Therapeutics A ticker?

The ticker of Nykode Therapeutics A is NYKD.OL.

How much dividend does Nykode Therapeutics A pay?

Over the past 12 months, Nykode Therapeutics A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nykode Therapeutics A is expected to pay a dividend of 0 USD.

What is the dividend yield of Nykode Therapeutics A?

The current dividend yield of Nykode Therapeutics A is .

When does Nykode Therapeutics A pay dividends?

Nykode Therapeutics A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nykode Therapeutics A?

Nykode Therapeutics A paid dividends every year for the past 0 years.

What is the dividend of Nykode Therapeutics A?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nykode Therapeutics A located?

Nykode Therapeutics A is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nykode Therapeutics A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nykode Therapeutics A from 3/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/7/2025.

When did Nykode Therapeutics A pay the last dividend?

The last dividend was paid out on 3/7/2025.

What was the dividend of Nykode Therapeutics A in the year 2024?

In the year 2024, Nykode Therapeutics A distributed 0 USD as dividends.

In which currency does Nykode Therapeutics A pay out the dividend?

The dividends of Nykode Therapeutics A are distributed in USD.

All fundamentals about Nykode Therapeutics A

Our stock analysis for Nykode Therapeutics A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nykode Therapeutics A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.